[Immunocorrective effect of cycloferon and thymogen in patients with uterine cancer].
Those women diagnosed as having hysterocarcinoma demonstrate even before surgery pronounced immunological disturbances tending to progress after surgical intervention. The employment of cyclopheronum and thymogenum makes for normalization of values for the immune status. Clinically, this is accompanied by a more favourable postoperative course.
Antipova
S V
SV
D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000936:Antigen-Antibody Complex / Q000097:blood; D015703:Antigens, CD / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D004151:Dipeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000097:blood / Q000276:immunology* / Q000601:surgery
D000166:Acridines; D000276:Adjuvants, Immunologic; D000936:Antigen-Antibody Complex; D015703:Antigens, CD; D004151:Dipeptides; C060736:thymogen; C026430:10-carboxymethyl-9-acridanone